1: Tang LF, Ma X, Xie LW, Zhou H, Yu J, Wang ZX, Li M. Perillaldehyde Mitigates Ionizing Radiation-Induced Intestinal Injury by Inhibiting Ferroptosis via the Nrf2 Signaling Pathway. Mol Nutr Food Res. 2023 Oct;67(19):e2300232. doi: 10.1002/mnfr.202300232. Epub 2023 Sep 1. PMID: 37658487.
2: Wei J, Liu Z, Sun H, Xu L. Perillaldehyde ameliorates lipopolysaccharide- induced acute lung injury via suppressing the cGAS/STING signaling pathway. Int Immunopharmacol. 2024 Mar 30;130:111641. doi: 10.1016/j.intimp.2024.111641. Epub 2024 Feb 18. PMID: 38368770.
3: Chu L, Li C, Li Y, Yu Q, Yu H, Li C, Meng W, Zhu J, Wang Q, Wang C, Cui S. Perillaldehyde Inhibition of cGAS Reduces dsDNA-Induced Interferon Response. Front Immunol. 2021 Apr 22;12:655637. doi: 10.3389/fimmu.2021.655637. PMID: 33968056; PMCID: PMC8100446.
4: Honma M, Yamada M, Yasui M, Horibata K, Sugiyama KI, Masumura K. In vivo and in vitro mutagenicity of perillaldehyde and cinnamaldehyde. Genes Environ. 2021 Jul 16;43(1):30. doi: 10.1186/s41021-021-00204-3. PMID: 34271990; PMCID: PMC8284016.
5: Erhunmwunsee F, Pan C, Yang K, Li Y, Liu M, Tian J. Recent development in biological activities and safety concerns of perillaldehyde from perilla plants: A review. Crit Rev Food Sci Nutr. 2022;62(23):6328-6340. doi: 10.1080/10408398.2021.1900060. Epub 2021 Mar 22. PMID: 33749409.
6: Yu YN, Ren YY, Shao ZL, Chen BL, Cui BY, Chao CY, Guo LJ, Guo S, Zhang MX, Wang SX, Zhu ML, Yin YL, Li P. Perillaldehyde improves diabetic cardiomyopathy by upregulating miR-133a-3p to regulate GSK-3β. Eur J Pharmacol. 2023 Aug 15;953:175836. doi: 10.1016/j.ejphar.2023.175836. Epub 2023 Jun 15. PMID: 37329971.
7: Liu S, Xu Y, Yao X, Cao H, Zhou H, Luo J, Gao H, Chen B, Chen H, Xie T, Zhan X. Perillaldehyde ameliorates sepsis-associated acute kidney injury via inhibiting HSP90AA1-mediated ferroptosis and pyroptosis: Molecular structure and protein interaction of HSP90AA1. Int J Biol Macromol. 2025 Apr;304(Pt 2):140954. doi: 10.1016/j.ijbiomac.2025.140954. Epub 2025 Feb 11. PMID: 39947536.
8: Chen L, Qu S, Yang K, Liu M, Li YX, Keller NP, Zeng X, Tian J. Perillaldehyde: A promising antifungal agent to treat oropharyngeal candidiasis. Biochem Pharmacol. 2020 Oct;180:114201. doi: 10.1016/j.bcp.2020.114201. Epub 2020 Aug 18. PMID: 32822688.
9: Catanzaro E, Turrini E, Kerre T, Sioen S, Baeyens A, Guerrini A, Bellau MLA, Sacchetti G, Paganetto G, Krysko DV, Fimognari C. Perillaldehyde is a new ferroptosis inducer with a relevant clinical potential for acute myeloid leukemia therapy. Biomed Pharmacother. 2022 Oct;154:113662. doi: 10.1016/j.biopha.2022.113662. Epub 2022 Sep 7. PMID: 36800294.
10: Wang G, Wang Y, Wang K, Zhao H, Liu M, Liang W, Li D. Perillaldehyde Functions as a Potential Antifungal Agent by Triggering Metacaspase-Independent Apoptosis in Botrytis cinerea. Microbiol Spectr. 2023 Jun 15;11(3):e0052623. doi: 10.1128/spectrum.00526-23. Epub 2023 May 16. PMID: 37191530; PMCID: PMC10269628.
11: Chu ZY, Li YL, Wang L, Wei SY, Yang SQ, Zeng H. Perillaldehyde: A promising antibacterial agent for the treatment of pneumonia caused by Acinetobacter baumannii infection. Int Immunopharmacol. 2024 Jan 5;126:111311. doi: 10.1016/j.intimp.2023.111311. Epub 2023 Dec 4. PMID: 38043271.
12: Fang M, Luo L, Chen Y, Liu Y, Yan Y, Wang F, Zou Y, Zhu H, Wu X, Jin Z, Huang C, Zhang Y, Fan S. Perillaldehyde Improves Parkinson-Like Deficits by Targeting G3BP Mediated Stress Granule Assembly in Preclinical Models. Adv Sci (Weinh). 2025 Apr;12(14):e2412152. doi: 10.1002/advs.202412152. Epub 2025 Feb 14. PMID: 39951026; PMCID: PMC11984871.
13: Niu QQ, Fu ZZ, Mao BY, Zhang X, Wang HD, Li P, Lin LB, Xi YT, Yin YL, Kamal NNSNM, Lim V. Perillaldehyde targeting PARP1 to inhibit TRPM2-CaMKII/CaN signal transduction in diabetic cardiomyopathy. Int Immunopharmacol. 2025 Mar 26;150:114291. doi: 10.1016/j.intimp.2025.114291. Epub 2025 Feb 18. PMID: 39970708.
14: Fang M, Liu Y, Gao X, Yu J, Tu X, Mo X, Zhu H, Zou Y, Huang C, Fan S. Perillaldehyde alleviates polyQ-induced neurodegeneration through the induction of autophagy and mitochondrial UPR in Caenorhabditis elegans. Biofactors. 2025 Jan-Feb;51(1):e2089. doi: 10.1002/biof.2089. Epub 2024 Jul 11. PMID: 38990058.
15: He M, You J, Liu X, Peng X, Li C, Yang S, Xu Q, Lin J, Zhao G. Perillaldehyde Protects Against Aspergillus fumigatus Keratitis by Reducing Fungal Load and Inhibiting Inflammatory Cytokines and LOX-1. Curr Eye Res. 2022 Oct;47(10):1366-1373. doi: 10.1080/02713683.2022.2093382. Epub 2022 Jun 30. PMID: 35759617.
16: Zheng W, Liu B, Shi E. Perillaldehyde Alleviates Spinal Cord Ischemia- Reperfusion Injury Via Activating the Nrf2 Pathway. J Surg Res. 2021 Dec;268:308-317. doi: 10.1016/j.jss.2021.06.055. Epub 2021 Aug 13. PMID: 34399353.
17: Lin Z, Huang S, LingHu X, Wang Y, Wang B, Zhong S, Xie S, Xu X, Yu A, Nagai A, Kobayashi Y, Wa Q, Huang S. Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines. Bioengineered. 2022 Feb;13(2):2710-2719. doi: 10.1080/21655979.2021.2001237. PMID: 34738877; PMCID: PMC8973720.
18: Burt S. Essential oils: their antibacterial properties and potential applications in foods--a review. Int J Food Microbiol. 2004 Aug 1;94(3):223-53. doi: 10.1016/j.ijfoodmicro.2004.03.022. PMID: 15246235.
19: Fuyuno Y, Uchi H, Yasumatsu M, Morino-Koga S, Tanaka Y, Mitoma C, Furue M. Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes. Oxid Med Cell Longev. 2018 Feb 14;2018:9524657. doi: 10.1155/2018/9524657. Erratum in: Oxid Med Cell Longev. 2018 May 22;2018:6091947. doi: 10.1155/2018/6091947. PMID: 29643980; PMCID: PMC5832143.
20: Zhang Y, Long Y, Yu S, Li D, Yang M, Guan Y, Zhang D, Wan J, Liu S, Shi A, Li N, Peng W. Natural volatile oils derived from herbal medicines: A promising therapy way for treating depressive disorder. Pharmacol Res. 2021 Feb;164:105376. doi: 10.1016/j.phrs.2020.105376. Epub 2020 Dec 11. PMID: 33316383.